ReviewIntensive care medicine2007
Management of invasive pulmonary aspergillosis in non-neutropenic critically ill patients.
Review in Intensive care medicine, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 1 synthesis or guideline pooled it, 140 citations in OpenAlex.
- A meta-analysis-informed diagnostic stratification tool for invasive pulmonary aspergillosis in severe fever with thrombocytopenia syndrome: systematic review, meta-analysis, and single-center cohort-based assessment.Frontiers in cellular and infection microbiology · 2026Pooled it
- Invasive aspergillosis in autoimmune inflammatory rheumatic diseases: epidemiology, risk factors, diagnosis, management and challenges.Annals of medicine · 2026Review
- Clinical application of BALF-mNGS in immunocompromised and immunocompetent patients with suspected invasive pulmonary aspergillosis: differentiating infection from colonization, microbiome features, and clinical impact.Microbiology spectrum · 2026Article
- Pathologic evaluation of Syzygium aromaticum essential oil against pulmonary aspergillosis in non-neutropenic immunosuppressed rabbits.Scientific reports · 2026Article
- Beyond detection: quantitative interpretation ofFrontiers in cellular and infection microbiology · 2026Article
- Pulmonary mucormycosis and aspergillosis co-infection in an immunocompetent host: a rare case report with review of literature.Indian journal of thoracic and cardiovascular surgery · 2025Article
- Metagenomic next-generation sequencing and galactomannan testing for the diagnosis of invasive pulmonary aspergillosis.Scientific reports · 2024Article
- Invasive pulmonary aspergillosis among patients with severe community-acquired pneumonia and influenza in ICUs: a retrospective cohort study.Pneumonia (Nathan Qld.) · 2024Article
- Value Evaluation of QuantitativeInfection and drug resistance · 2024Article
- Article
- Metabolome and Transcriptome Combinatory Profiling Reveals Fluconazole Resistance Mechanisms ofMicroorganisms · 2023Article
- Article
- The Novel Monoclonal IgGJournal of fungi (Basel, Switzerland) · 2023Article
- Invasive Pulmonary Aspergillosis in Coronavirus Disease 2019 Patients Lights and Shadows in the Current Landscape.Advances in respiratory medicine · 2023Review
- Investigation of predictors for invasive pulmonary aspergillosis in patients with severe fever with thrombocytopenia syndrome.Scientific reports · 2023Article
- Article
- Article
- PulmonarySultan Qaboos University medical journal · 2021Article
- Comparative Genome Sequence Analyses of Geographic Samples ofMicroorganisms · 2020Article
- Opportunistic invasive fungal disease in patients with type 2 diabetes mellitus from Southern China: Clinical features and associated factors.Journal of diabetes investigation · 2020Article
Corrections and comments
- Commented on by
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
During recent years, a rising incidence of invasive pulmonary aspergillosis (IPA) in non-neutropenic critically ill patients has been reported. Critically ill patients are prone to develop disturbances in immunoregulation during their stay in the ICU, which render them more vulnerable for fungal infections. Risk factors such as chronic obstructive pulmonary disease (COPD), prolonged use of steroids, advanced liver disease, chronic renal replacement therapy, near-drowning and diabetes mellitus have been described. Diagnosis of IPA may be difficult and obtaining histo- or cytopathological demonstration of the fungus in order to meet the gold standard for IPA is not always feasible in these patients. Laboratory markers used as a non-invasive diagnostic tool, such as the galactomannan antigen test (GM), 1,3-beta-glucan, and Aspergillus PCR, show varying results. Antifungal therapy might be considered in patients with persistent pulmonary infection who exhibit risk factors together with positive cultures or sequentially positive GM and Aspergillus PCR in serum, in whom voriconazole is the drug of choice. The benefit of combination antifungal therapy lacks sufficient evidence so far, but this treatment might be considered in patients with breakthrough infections or refractory disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.